Clear All
11465 Matching Results — Export these results
Click column titles once to sort ascending, and twice to sort descending.
NDC-11 (Package) NDC-9 (Product) Generic Name Brand Name Strength SEER*Rx Category Major Class Minor Class Administration Route Package Effective Date Package Discontinuation Date Status
00002-4184-07 00002-4184 Raloxifene Hydrochloride Evista 60.0 mg/1 Hormonal Therapy Selective Estrogen Receptor Modulator (SERM) Oral Dec 16, 2016 Nov 30, 2019 In Use
42291-0726-90 42291-0726 Raloxifene Hydrochloride Raloxifene Hydrochloride 60.0 mg/1 Hormonal Therapy Selective Estrogen Receptor Modulator (SERM) Oral Nov 3, 2014 Sep 19, 2018 In Use
43598-0505-01 43598-0505 Raloxifene hydrochloride Raloxifene Hydrochloride 60.0 mg/1 Hormonal Therapy Selective Estrogen Receptor Modulator (SERM) Oral Oct 12, 2016 In Use
65862-0709-99 65862-0709 Raloxifene Hydrochloride Raloxifene Hydrochloride 60.0 mg/1 Hormonal Therapy Selective Estrogen Receptor Modulator (SERM) Oral Aug 28, 2015 In Use
69189-2367-01 69189-2367 Raloxifene Hydrochloride Raloxifene 60.0 mg/1 Hormonal Therapy Selective Estrogen Receptor Modulator (SERM) Oral May 9, 2016 May 24, 2017 No Longer Used
65862-0709-10 65862-0709 Raloxifene Hydrochloride Raloxifene Hydrochloride 60.0 mg/1 Hormonal Therapy Selective Estrogen Receptor Modulator (SERM) Oral Aug 28, 2015 In Use
50268-0694-15 50268-0694 Raloxifene Hydrochloride Raloxifene Hydrochloride 60.0 mg/1 Hormonal Therapy Selective Estrogen Receptor Modulator (SERM) Oral Jun 27, 2018 In Use
70518-3046-00 70518-3046 Raloxifene Raloxifene Hydrochloride 60.0 mg/1 Hormonal Therapy Selective Estrogen Receptor Modulator (SERM) Oral Mar 11, 2021 In Use
00002-7678-01 00002-7678 Ramucirumab Cyramza 10.0 mg/mL Immunotherapy Monoclonal Antibody VEGF Intravenous Apr 21, 2014 In Use
00002-7669-01 00002-7669 Ramucirumab Cyramza 10.0 mg/mL Immunotherapy Monoclonal Antibody VEGF Intravenous Apr 21, 2014 In Use
00024-5150-10 00024-5150 Rasburicase Elitek Ancillary Therapy Metabolic Agent Enzyme Jul 12, 2002 In Use
00024-5151-75 00024-5151 Rasburicase Elitek Ancillary Therapy Metabolic Agent Enzyme Jun 1, 2006 In Use
50419-0171-03 50419-0171 Regorafenib Stivarga 40.0 mg/1 Chemotherapy Tyrosine Kinase Inhibitor VEGF, FGF, PDGFR, KIT, RET, TIE2, DDR2, TrkQ, RAF, BRAF, SAPK2, PTK, Abl Oral Sep 27, 2012 In Use
50419-0171-04 50419-0171 Regorafenib Stivarga 40.0 mg/1 Chemotherapy Tyrosine Kinase Inhibitor VEGF, FGF, PDGFR, KIT, RET, TIE2, DDR2, TrkQ, RAF, BRAF, SAPK2, PTK, Abl Oral Sep 27, 2012 In Use
50419-0171-00 50419-0171 Regorafenib Stivarga 40.0 mg/1 Chemotherapy Tyrosine Kinase Inhibitor VEGF, FGF, PDGFR, KIT, RET, TIE2, DDR2, TrkQ, RAF, BRAF, SAPK2, PTK, Abl Oral Sep 27, 2012 In Use
50419-0171-01 50419-0171 Regorafenib Stivarga 40.0 mg/1 Chemotherapy Tyrosine Kinase Inhibitor VEGF, FGF, PDGFR, KIT, RET, TIE2, DDR2, TrkQ, RAF, BRAF, SAPK2, PTK, Abl Oral Sep 27, 2012 In Use
50419-0171-06 50419-0171 Regorafenib Stivarga 40.0 mg/1 Chemotherapy Tyrosine Kinase Inhibitor VEGF, FGF, PDGFR, KIT, RET, TIE2, DDR2, TrkQ, RAF, BRAF, SAPK2, PTK, Abl Oral May 1, 2021 In Use
72974-0120-01 72974-0120 Relugolix Orgovyx 120.0 mg/1 Hormonal Therapy Androgen Receptor Inhibitor GnRH Receptor Antagonist Oral Dec 18, 2020 In Use
72974-0120-95 72974-0120 Relugolix Orgovyx 120.0 mg/1 Hormonal Therapy Androgen Receptor Inhibitor GnRH Receptor Antagonist Oral Jan 27, 2023 In Use
72974-0120-97 72974-0120 Relugolix Orgovyx 120.0 mg/1 Hormonal Therapy Androgen Receptor Inhibitor GnRH Receptor Antagonist Oral Oct 21, 2021 In Use
00003-4160-14 00003-4160 Repotrectinib Augtyro 160.0 mg/1 Chemotherapy Tyrosine Kinase Inhibitor ROS1, TRKA, TRKB, TRKC Oral Nov 1, 2024 In Use
00003-4040-60 00003-4040 Repotrectinib Augtyro 40.0 mg/1 Chemotherapy Tyrosine Kinase Inhibitor ROS1, TRKA, TRKB, TRKC Oral Dec 5, 2023 In Use
00003-4040-12 00003-4040 Repotrectinib Augtyro 40.0 mg/1 Chemotherapy Tyrosine Kinase Inhibitor ROS1, TRKA, TRKB, TRKC Oral Dec 5, 2023 In Use
00003-4160-60 00003-4160 Repotrectinib Augtyro 160.0 mg/1 Chemotherapy Tyrosine Kinase Inhibitor ROS1, TRKA, TRKB, TRKC Oral Nov 1, 2024 In Use
50881-0006-03 50881-0006 Retifanlimab-dlwr ZYNYZ 25.0 mg/mL Immunotherapy Checkpoint Inhibitor PD-1 Intravenous Mar 22, 2023 In Use

Found 11465 results — Export these results